$25.49
0.82% yesterday
Nasdaq, May 13, 10:15 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$25.49
-1.31 4.89% 1M
-16.65 39.51% 6M
-16.09 38.70% YTD
-100.18 79.72% 1Y
-112.42 81.52% 3Y
-39.69 60.89% 5Y
+6.89 37.04% 10Y
Nasdaq, Closing price Tue, May 13 2025
-0.21 0.82%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Market capitalization $9.86b
Enterprise Value $4.63b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.46
P/S ratio (TTM) P/S ratio 3.10
P/B ratio (TTM) P/B ratio 0.98
Revenue growth (TTM) Revenue growth -38.25%
Revenue (TTM) Revenue $3.18b
EBIT (operating result TTM) EBIT $-3.73b
Free Cash Flow (TTM) Free Cash Flow $-4.02b
Cash position $5.98b
EPS (TTM) EPS $-8.72
P/E forward negative
P/S forward 4.79
EV/Sales forward 2.25
Short interest 21.62%
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Moderna forecast:

6x Buy
21%
19x Hold
66%
4x Sell
14%

Analyst Opinions

29 Analysts have issued a Moderna forecast:

Buy
21%
Hold
66%
Sell
14%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3,177 3,177
38% 38%
100%
- Direct Costs 1,650 1,650
64% 64%
52%
1,527 1,527
167% 167%
48%
- Selling and Administrative Expenses 920 920
2% 2%
29%
- Research and Development Expense 4,144 4,144
1% 1%
130%
-3,537 -3,537
23% 23%
-111%
- Depreciation and Amortization 192 192
67% 67%
6%
EBIT (Operating Income) EBIT -3,729 -3,729
28% 28%
-117%
Net Profit -3,357 -3,357
44% 44%
-106%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Neutral
Schaeffers Research
about 20 hours ago
Stay on our website for longer than five minutes and you're bound to find references to Schaeffer's Volatility Scorecard (SVS). The internal metric is a goldmine for options traders, helping identify opportunities using a scored rating of volatility expectations in the last year. But there's more to SVS than meets the eye; the hypothetical straddle trades that are foundational to SVS can be tak...
Positive
Investors Business Daily
about 23 hours ago
Savvy investors know that buying leading growth stocks is the best way to profit long term. But there's a rush to buy the dip in the S&P 500.
Neutral
WSJ
2 days ago
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today